103626-36-4

Basic information

• Product Name: 9H-Purin-6-amine, N-cyclopentyl-
• Synonyms: 9H-Purin-6-amine, N-cyclopentyl-
• CAS NO: 103626-36-4
• Molecular Formula: C₁₀H₁₃N₅
• Molecular Weight: 0
• Mol File: 103626-36-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9H-Purin-6-amine, N-cyclopentyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-Purin-6-amine, N-cyclopentyl-(103626-36-4)
• EPA Substance Registry System: 9H-Purin-6-amine, N-cyclopentyl-(103626-36-4)

Safety Data

• Hazardous Substances Data: 103626-36-4(Hazardous Substances Data)

Upstream product

• 87-42-3 6-chloropurine 
• 1003-03-8 Cyclopentamine 

Relevant articles and documents

Synthesis and biological evaluation of disubstituted N6- cyclopentyladenine analogues: The search for a neutral antagonist with high affinity for the adenosine A1 receptor

Novel 3,8- and 8,9-disubstituted N6-cyclopentyladenine derivatives were synthesised in moderate overall yield from 6-chloropurine. The derivatives were made in an attempt to find a new neutral antagonist with high affinity for adenosine A1 receptors. N6-Cyclopentyl-9- methyladenine (N-0840) was used as a lead compound. Binding affinities of the new analogues were determined for human adenosine A1 and A 3 receptors. Their intrinsic activity was assessed in [ 35S]GTPγS binding experiments. Elongation of the 9-methyl of N-0840 to a 9-propyl substituent was very well tolerated. A 9-benzyl group, on the other hand, caused a decrease in adenosine A1 receptor affinity. Next, the 8-position was examined in detail, and affinity was increased with appropriate substitution. Most derivatives were A1-selective and 20 of the new compounds (6-9, 15-21, 23-26, 28, 31, 33, 35, and 36) had higher adenosine A1 receptor affinity than the reference substance, N-0840. Compound 31 (N6-cyclopentyl-8-(N-methylisopropylamino)-9- methyladenine, LUF 5608) had the highest adenosine A1 receptor affinity, 7.7 nM. In the [35S]GTPγS binding experiments, derivatives 5, 14, 22, 23, 25, 26, 33 and 34 did not significantly change basal [35S]GTPγS binding, thus behaving as neutral antagonists. Moreover, four of these compounds (23, 25, 26, and 33) displayed a 4- to 10-fold increased adenosine A1 receptor affinity (75-206 nM) compared to N-0840 (852 nM). In summary, we synthesised a range of N-0840 analogues with higher affinity for adenosine A1 receptors. In addition, four new derivatives, LUF 5666 (23), LUF 5668 (25), LUF 5669 (26) and LUF 5674 (33), behaved as neutral antagonists when tested in [ 35S]GTPγS binding studies. Thus, these compounds have improved characteristics as neutral adenosine A1 receptor antagonists.

Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

Inhibitors of MAPK/Erk Kinase

The present invention relates to compounds useful as inhibitors of MEK kinase and methods for the treatment or prevention of cellular proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.